Clinical trial
Seizure Therapy With Intravenous Levetiracetam and Lorazepam
NCT00465244 · Massachusetts General Hospital, Other · Withdrawn
Key facts
| NCT number | NCT00465244 |
|---|---|
| Title | Seizure Therapy With Intravenous Levetiracetam and Lorazepam |
| Official title | Seizure Therapy With Intravenous Levetiracetam and Lorazepam |
| Acronym | STILL |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | UCB Pharma Industry |
| Status | Withdrawn |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Seizures |
| Intervention type | Drug |
| Interventions | Levetiracetam 1 g IV + Lorazepam 2 mg IV, Placebo + Lorazepam 3 mg IV |
| Enrollment | 0 |
| Start date | Jan 1, 2008 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Apr 24, 2007 |
| Last update posted | Nov 1, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: